Brief Title
ARON-2 Study-Multicentric International Retrospective Study
Official Title
ARON-2 Study-Multicentric International Retrospective Study
Brief Summary
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy.
Study Type
Observational
Primary Outcome
Overall Survival (OS) of patients with metastatic Urothelial Cancer (UC) treated with pembrolizumab
Secondary Outcome
prognostic role of smoking attitude, obesity and concomitant medications in patients treated with pembrolizumab
Condition
Urothelial Carcinoma
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
367
Start Date
February 17, 2022
Completion Date
November 1, 2022
Primary Completion Date
September 30, 2022
Eligibility Criteria
Inclusion Criteria: - Patients aged >18y - Histologically confirmed diagnosis of UC of upper and/or lower urinary tract - Histologically or radiologically confirmed metastatic disease - Treatment with pembrolizumab in patients progressed after previous platinum-based chemotherapy - Treatment with pembrolizumab as first-line therapy in patients platinum-unfit - At least 1 cycle of pembrolizumab within the period from 1 January 2018 to 30 November 2021 Exclusion Criteria: - Patients without histologically confirmed diagnosis of UC - Patients without histologically or radiologically confirmed metastatic disease
Gender
All
Ages
18 Years - N/A
Contacts
, +39 07332572960, [email protected]
Location Countries
Italy
Location Countries
Italy
Administrative Informations
NCT ID
NCT05290038
Organization ID
ARON-2
Responsible Party
Sponsor-Investigator
Study Sponsor
Matteo Santoni
Study Sponsor
, ,
Verification Date
March 2022